NCT00444587View on ClinicalTrials.gov

A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Second line chemotherapy

As prescribed

DRUG

trastuzumab [Herceptin]

6mg/kg iv every 3 weeks

Trial Locations (30)

1000

Skopje

1082

Budapest

1115

Budapest

1122

Budapest

1125

Budapest

1135

Budapest

1145

Budapest

1527

Sofia

4032

Debrecen

4400

Nyíregyháza

5700

Gyula

6725

Szeged

8000

Székesfehérvár

9023

Győr

9700

Szombathely

13110

Safed

13419

Tallinn

31096

Haifa

49100

Petah Tikva

50009

Kaunas

52621

Ramat Gan

58100

Holon

70300

Ẕerifin

76100

Rehovot

6423906

Tel Aviv

08660

Vilnius

812 50

Bratislava

041 90

Košice

01330

Adana

06590

Ankara

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00444587 - A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | Biotech Hunter | Biotech Hunter